Kiniksa (KNSA) Pharmaceuticals International provided a corporate update. Key highlights: ARCALYST 2025 net product revenue of $677.5 million, representing ~62% year-over-year growth; ARCALYST 2026 net product revenue expected to be $900 – $920 million; KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; KPL-1161 Phase 1 trial planned to initiate by year end; Cash balance increased by $170.4 million in 2025 to $414.1 million
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA: